PARP inhibitors in the management of breast cancer: current data and future prospects.

BMC Med · 2015 · PMC4535298 · PMID 26268938

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[ 6 ], response rate to olaparib across breast cancer patients showed a trend in favor of patients without prior platinum exposure.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.